Mountain Pacific Investment Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$290K Hold
315
0.05% 125
2025
Q4
$339K Sell
315
-529
-63% -$506K 0.05% 124
2025
Q3
$644K Hold
844
0.1% 97
2025
Q2
$658K Buy
844
+489
+138% +$380K 0.05% 97
2025
Q1
$293K Hold
355
0.02% 131
2024
Q4
$274K Sell
355
-30
-8% -$24.8K 0.02% 125
2024
Q3
$341K Hold
385
0.02% 125
2024
Q2
$349K Hold
385
0.03% 122
2024
Q1
$300K Hold
385
0.02% 126
2023
Q4
$224K Sell
385
-25
-6% -$14.6K 0.01% 129
2023
Q3
$220K Buy
+410
New +$211K 0.02% 126

Other funds holding LLY

Mountain Pacific Investment Advisers's LLY Position: Q1 2026 in Review

Mountain Pacific Investment Advisers held its Eli Lilly (LLY) position steady in Q1 2026 at 315 shares worth $290K. The position accounts for 0.05% of the portfolio, ranked #125.

Mountain Pacific Investment Advisers first reported a position in LLY in Q3 2023 and has held it in 11 quarters since. The position peaked at $658K in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mountain Pacific Investment Advisers held 315 shares of Eli Lilly worth $290K as of Q1 2026.
  • Mountain Pacific Investment Advisers left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.05% of Mountain Pacific Investment Advisers's portfolio in Q1 2026, its #125 holding.
  • Mountain Pacific Investment Advisers first reported a position in Eli Lilly in Q3 2023 and has held it in 11 quarters since.
  • Mountain Pacific Investment Advisers's Eli Lilly position peaked at $658K in Q2 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mountain Pacific Investment Advisers's 13F filing for Q1 2026, filed 16 Apr 2026.